Skip to content
2000
Volume 27, Issue 27
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

The global prevalence of NAFLD is estimated to be over 25% and it is already the leading cause of chronic liver disease in industrialized countries, as a consequence of the spread of obesity and metabolic syndrome. The prognosis of NAFLD is generally benign in the absence of fibrosis, but liver fibrosis rapidly progresses in 20% of the cases and can lead to cirrhosis and/or HCC. This review focuses on non-invasive fibrosis testing strategies for patients with NAFLD in order to increase the efficiency and effectiveness of diagnosis and care, regulating secondary care referral fluxes. An integrated management plan between primary care and secondary care with a defined algorithm of non-invasive testing to stratify the risk of NAFLD fibrosis is indispensable to increase the early diagnosis of fibrosis but also decrease unnecessary referrals.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612827666210127120748
2021-08-01
2025-04-04
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612827666210127120748
Loading

  • Article Type:
    Review Article
Keyword(s): cirrhosis; ELF; FIB-4; non-invasive fibrosis tests; primary care; Steatohepatitis
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test